



Jazz Pharmaceuticals to Hold Investor Conference Call on January 5 to Discuss 2012 Financial Guidance and Azur Pharma Transaction

January 4, 2012

-- Company to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 11 --

PALO ALTO, Calif., Jan. 4, 2012 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced two upcoming investor events:

- The company will hold a conference call on January 5, 2012 at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time to discuss high-level 2012 financial guidance and the anticipated timing of the closing for the business combination with Azur Pharma, and to provide an update on growth of Xyrem® (sodium oxybate). A live webcast of the conference call may be accessed from the Investors section of the Jazz Pharmaceuticals website at <http://www.jazzpharmaceuticals.com/>. Investors may participate in the conference call by dialing 866-825-1692 in the U.S., or 617-213-8059 outside the U.S., and entering passcode 88638936.
- In addition, Bruce Cozadd, the company's chairman and chief executive officer, will provide a business update at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2012 at 10:30 a.m. Pacific Time/1:30 p.m. Eastern Time. A live webcast of the J.P. Morgan presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at <http://www.jazzpharmaceuticals.com/>.

To access the live webcast for these events, please connect to the Jazz Pharmaceuticals website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. An archived version of both webcasts will be available for at least one week on the Investors section of the company's website at <http://www.jazzpharmaceuticals.com/>.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals (Nasdaq: JAZZ) is a specialty biopharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs. For further information, see <http://www.jazzpharmaceuticals.com/>.

SOURCE Jazz Pharmaceuticals, Inc.

Ami Knoefler, Executive Director, Investor Relations & Corporate Communications of Jazz Pharmaceuticals, Inc., +1-650-496-2947, ami.knoefler@jazzpharma.com